Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 31c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of ($1.75), $0.31 worse than the analyst estimate of ($1.44). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $21.74 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike
• Corpay agrees to $100M FTC settlement over marketing practices